NHLBI Blood /Marrow Transplant Clinical Research Network

NHLBI 血液/骨髓移植临床研究网络

• 批准号: 7897784
• 负责人: HILLARD M LAZARUS
• 金额: $ 11.52万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-30 至 2011-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7897784
• 关键词: Address; Ancillary Study; Area; Attention; Blood; Childhood; Clinical; Clinical Research; Clinical Trials; Clinical Trials Network; Collaborations; Complement; Complex; Disease; Funding; Hematopoietic Stem Cell Transplantation; Hematopoietic stem cells; Immune; Inborn Genetic Diseases; Infection; Late Effects; Malignant - descriptor; Malignant Neoplasms; Marrow; National Heart, Lung, and Blood Institute; Non-Malignant; Outcome; Patients; Phase; Phase III Clinical Trials; Population; Quality of life; Recurrence; Regimen; Relapse; Research; Resources; Source; Toxic effect; Transplantation; graft vs host disease; improved; prospective; reconstitution

Hematopoietic stem cell (HCT) transplantation offers curative therapy for a variety of malignant and non-malignant disorders. It is limited by donor availability, transplant related toxicity, graft vs. host disease (GVHD), malignant relapse, infections, and for some patients, reduction in their post- transplant quality of life. Continuing progress from the previous funding period, the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) proposes to develop and execute scientifically meritorious, prospective clinical trials addressing key issues in HCT. We will conduct multicenter Phase II and more importantly, prospective Phase III trials, in six key areas including: alternative donors and graft sources; regimen related toxicity; GVHD; disease recurrence; infection and immune reconstitution; and late effects and quality of life. Due to the complexity of pediatric transplantation, especially in those with rare inherited disorders, which are complex and difficult to study, we will devote special attention and focused scientific expertise to using the coordinated strength of the Network to improve BMT outcomes for this unique population. The BMT CTN will also amplify and leverage Network resources through collaborative research and ancillary studies of biologic endpoints that will be integrated with and complement clinical endpoints. The Network will also seek active collaboration with other scientific bodies including NCI- funded Cancer Cooperative Groups to improve the efficiency of clinical transplant studies for the large number of patients who could benefit from BMT and to maximize our successful completion of high quality and high priority clinical trials.

造血干细胞（HCT）移植为各种恶性肿瘤和恶性肿瘤提供了治愈性治疗。 非恶性疾病。它受到供体可用性、移植相关毒性、移植物与宿主的限制 疾病（GVHD），恶性复发，感染，以及对一些患者来说，减少他们的后 移植生活质量。从上一个资助期开始，血液和 骨髓移植临床试验网络（BMT CTN）建议开发和执行 具有科学价值的前瞻性临床试验，解决HCT中的关键问题。我们会进行 多中心II期试验，更重要的是前瞻性III期试验，涉及六个关键领域，包括： 替代供体和移植物来源;方案相关毒性; GVHD;疾病复发;感染 和免疫重建;以及晚期效应和生活质量。由于儿科的复杂性， 移植，特别是在那些罕见的遗传性疾病，这是复杂和困难的， 我们将特别注意和集中科学专门知识， 该网络的优势，以改善这一独特人群的BMT结果。BMT CTN将 还通过以下方面的合作研究和辅助研究，扩大和利用网络资源 生物学终点将与临床终点整合并补充临床终点。该网络将 我还寻求与其他科学机构的积极合作，包括NCI资助的癌症合作组织 组，以提高效率的临床移植研究的大量患者谁 可以从BMT中受益，并最大限度地成功完成高质量和高优先级 临床试验

项目成果

Emerging therapeutic approaches for multipotent mesenchymal stromal cells.

多能间充质基质细胞的新兴治疗方法。

• DOI: 10.1097/moh.0b013e32833e5b18
• 发表时间: 2010-11
• 期刊: Current opinion in hematology
• 影响因子: 3.2
• 作者: Caimi PF;Reese J;Lee Z;Lazarus HM
• 通讯作者: Lazarus HM